November 27, 2024

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

Key Points

Key points are not available for this paper at this time.

Abstract

The HIV incidence with twice-yearly lenacapavir was significantly lower than the background incidence and the incidence with F/TDF. (Funded by Gilead Sciences; PURPOSE 2 ClinicalTrials.gov number, NCT04925752.).

Bookmark

Cite This Study

Kelley et al. (Wed,) studied this question.

synapsesocial.com/papers/69d75bc7086f9d6299f30a80 https://doi.org/https://doi.org/10.1056/nejmoa2411858

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The impact of the M184V resistance mutation on treatment outcomes in patients with HIV infection: a systematic review and meta-analysis2023 · 11 citations
2Racial/Ethnic Disparities in HIV Preexposure Prophylaxis Among Men Who Have Sex with Men — 23 Urban Areas, 20172019 · 289 citations
3Recent HIV Infection and Annualized HIV Incidence Rates Among Sexual and Gender Minorities in Brazil and Peru (ImPrEP Seroincidence Study): A Cross-Sectional, Multicenter Study2023 · 26 citations
4Clinical targeting of HIV capsid protein with a long-acting small molecule2020 · 421 citations
5Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand2021 · 15 citations

Bookmark